Scinai Immunotherapeutics Ltd.

Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.

SCNI | US

Overview

Corporate Details

ISIN(s):: US09073Q3039 (+1 more)
LEI:
Country:: United States of America
Address:: JERUSALEM BIOPARK, 2ND FLOOR, 0 JERUSALEM
Website:: https://www.scinai.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Scinai Immunotherapeutics is a biopharmaceutical company with a dual business model focused on inflammation and immunology (I&I). The company develops a proprietary pipeline of biological products, including alpaca-derived nanosized antibodies (NanoAbs) for autoimmune and infectious diseases, in collaboration with institutions like the Max Planck Institute. Additionally, its Scinai Bio-services business unit operates as a Contract Development and Manufacturing Organization (CDMO), providing comprehensive services to other pharmaceutical and biotech companies. These services span process and analytical development, scale-up, and cGMP manufacturing for nonclinical and clinical studies from its state-of-the-art facility.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Scinai Immunotherapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Scinai Immunotherapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Scinai Immunotherapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Enlivex Therapeutics Ltd. Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.	United States of America	ENLV
Enorama Pharma AB Develops & makes consumer nicotine products & medicated gums, offering private label solutions.	Sweden	ERMA
Ensysce Biosciences, Inc. Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.	United States of America	ENSC
Entera Bio Ltd. Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.	United States of America	ENTX
Entero Therapeutics, Inc. Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.	United States of America	ENTO
Entrada Therapeutics, Inc. Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.	United States of America	TRDA
ENZYCHEM LIFESCIENCES CORPORATION Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.	South Korea	183490
Enzymatica AB Develops medical devices with patented enzyme technology to treat upper respiratory infections.	Sweden	ENZY
Epi Biotech Co., Ltd. Developing alopecia therapies, skin regeneration products, and preclinical CRO services.	South Korea	446440
EQL Pharma AB Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.	Sweden	EQL